29
By Josh Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC
One morning in early June I was reading my LinkedIn feed and saw something that caught my eye – a university was establishing a minor in science and patient advocacy. I hadn’t heard of a college formalizing a program focused on preparing the next generation to become advocates. I was inspired by the innovative nature of the program and felt an immediate connection to the possibilities as CEO of a company that has made delivering for patients the center of our mission and as a graduate of the university launching the program, Notre Dame.
Source link